WO2002013847A3 - Methods for diagnosis and therapy of hematological and virus-associated malignancies - Google Patents

Methods for diagnosis and therapy of hematological and virus-associated malignancies

Info

Publication number
WO2002013847A3
WO2002013847A3 PCT/US2001/025408 US0125408W WO2002013847A3 WO 2002013847 A3 WO2002013847 A3 WO 2002013847A3 US 0125408 W US0125408 W US 0125408W WO 2002013847 A3 WO2002013847 A3 WO 2002013847A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
methods
neu
sequences
hematological
virus
Prior art date
Application number
PCT/US2001/025408
Other languages
French (fr)
Other versions
WO2002013847A2 (en )
Inventor
Alexander Gaiger
Martin A Cheever
Susan Hand-Zimmermann
Original Assignee
Corixa Corp
Alexander Gaiger
Martin A Cheever
Susan Hand-Zimmermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.
PCT/US2001/025408 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies WO2002013847A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US63828000 true 2000-08-14 2000-08-14
US09/638,280 2000-08-14
US67590400 true 2000-09-28 2000-09-28
US09/675,904 2000-09-28

Publications (2)

Publication Number Publication Date
WO2002013847A2 true WO2002013847A2 (en) 2002-02-21
WO2002013847A3 true true WO2002013847A3 (en) 2002-12-19

Family

ID=27093044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025408 WO2002013847A3 (en) 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Country Status (1)

Country Link
WO (1) WO2002013847A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583833A1 (en) 2003-01-03 2005-10-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus her2/neu, nucleotides encoding same, and uses thereof
ES2605443T3 (en) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
RU2404810C9 (en) 2004-06-01 2015-06-20 Дженентек, Инк. Conjugates antibody-medicinal agent and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
JP5972864B2 (en) 2010-04-15 2016-08-17 メディミューン リミテッド Pyrrolo benzodiazepines and their conjugates
CN107335062A (en) 2010-06-08 2017-11-10 基因泰克公司 Cysteine engineered antibodies and conjugates
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2530968T3 (en) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas and conjugates thereof
DK2906251T3 (en) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
KR20150085814A (en) 2012-10-12 2015-07-24 에이디씨 테라퓨틱스 에스에이알엘 Pyrrolobenzodiazepine-antibody conjugates
CN105209077A (en) 2013-03-13 2015-12-30 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
KR20150131203A (en) 2013-03-13 2015-11-24 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3033111A1 (en) 2013-08-12 2016-06-22 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082875A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
US20160074528A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CA2996902A1 (en) 2015-10-02 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
US20170112891A1 (en) 2015-10-16 2017-04-27 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROSSART PETER ET AL: "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 96, no. 9, 1 November 2000 (2000-11-01), pages 3102 - 3108, XP002172006, ISSN: 0006-4971 *
BUHRING H-J ET AL: "THE RECEPTOR TYROSINE KINASE P185 HER2 IS EXPRESSED ON A SUBSET OF B-LYMPHOID BLASTS FROM PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND CHRONIC MYELOGENOUS LEUKEMIA", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 86, no. 5, 1 September 1995 (1995-09-01), pages 1916 - 1923, XP000560897, ISSN: 0006-4971 *
DISIS M L ET AL: "Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, no. 9, 1 May 1996 (1996-05-01), pages 3151 - 3158, XP002139506, ISSN: 0022-1767 *
GALY A ET AL: "Generation of immunogenic dendritic cells that are gene-modified to present the ERBB2 antigen.", IMMUNOLOGY, vol. 92, no. SUPPL. 1, December 1997 (1997-12-01), 5th Annual Congress of the British Society for Immunology;Brighton, England, UK; December 2-5, 1997, pages 12, XP001074064, ISSN: 0019-2805 *
IMAMURA N ET AL: "AGGRESSIVE DIFFUSE LYMPHOMA COEXPRESSING NRAS P21 AND C-ERBB-2 (NEU) ONCOGENE PRODUCTS, AND CALLA (CD10)", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 4, no. 5/6, 1991, pages 419 - 422, XP000560889, ISSN: 1042-8194 *
TIMMERMAN J M ET AL: "DENDRITIC CELL VACCINES FOR CANCER IMMUNOTHERAPY", ANNUAL REVIEW OF MEDICINE: SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 50, 1999, pages 507 - 529, XP001005422, ISSN: 0066-4219 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date Type
WO2002013847A2 (en) 2002-02-21 application

Similar Documents

Publication Publication Date Title
GB2379878B (en) Electrosurgical system and method
Cuschieri Approach to the treatment of acute cholecystitis: open surgical, laparoscopic or endoscopic?
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2001032926A3 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
WO2004050707A3 (en) Tumor-specific recognition molecules
Maccarini et al. Simple endoscopic treatment of a granular-cell tumor of the esophagus
WO2004048551A3 (en) Target for therapy of cognitive impairment
Chang et al. Endoscopic treatment of bleeding fundic varices with 50% glucose injection
WO2002016412A3 (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
CA2332733A1 (en) Signal peptides, nucleic acid molecules and methods for treatment of caries
Tanno et al. Endoscopic treatment of gallstone-impacted choledochocele precisely diagnosed by endoscopic ultrasonography
DE29912449U1 (en) Mixture for the preservation of rocks and lime and cement-based plasters and cement-stones
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
WO2003053383A3 (en) Cosmetic use of at least a hydrophobin for treating keratinous materials
WO2003008583A3 (en) Novel compositions and methods for cancer
GB2344815B (en) Landfill leachate treatment
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2002069783A3 (en) Device and methods for treating vascular malformations
VALTERS et al. Analysis of organohalogen substances in Latvian freshwater fish-concentrations of PCB and DDE in perch (Perca fluviatilis)
Yoshikane et al. Lymphangioma of the colon treated by endoscopic resection following fine-needle puncture aspiration
WO2003048315A3 (en) Antisense modulation of mdm2 expression
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO1999054326A8 (en) Dihydropyrimidines

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP